Characterisation of cells markers associated with IKZF1plus in BCP-ALL

The presence of IKZF1 deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of IKZF1<sup>del</sup> cases called IKZF1<sup>plus</sup> (defined by the co-occurrence of IKZF1<sup>del</sup> and deletions in CDKN2A/B, PAX5, or the PAR1 region, in the absence of ERG deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the IKZF1<sup>del</sup> and IKZF1<sup>plus</sup> groups. Therefore, the IKZF1<sup>plus</sup> group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with IKZF1<sup>plus</sup>. Two independent series of cases (TARGET, n = 125 and GenLAb, n = 60) were evaluated by segregating patients into 3 groups: IKZF1<sup>plus</sup>, IKZF1<sup>del</sup>, and IKZF1<sup>wild</sup>. Differential expression analyses showed that the membrane protein-coding genes most associated with the IKZF1<sup>plus</sup> group were: KCNA5, GREB1, EPOR, SDK1, and PTPRB. Notably, KCNA5 and GREB1 differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of VPREB1 deletions in the IKZF1<sup>plus</sup> group, as well as additional exclusive deletions in the CD200 and BTLA genes. Recent research suggests that the importance of the IKZF1<sup>plus</sup> profile varies depending on the genetic subgroup. In this scenario, we found associations between IKZF1<sup>plus</sup> and certain genes in BCP-ALL, being KCNA5 and GREB1 the most promising biomarkers for predicting IKZF1<sup>plus</sup>. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2024-09-23
DOI
https://doi.org/10.1016/j.tranon.2024.102127
Citations
2
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
1.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Characterisation of cells markers associated with IKZF1plus in BCP-ALL

Maura Rosane Valério Ikoma-Coltutato, Marcia Schramm, Caroline P. Poubel, Mecneide Mendes Lins et al.
2 citations
Translational Oncology
Acute Lymphoblastic Leukemia research
1.09
article

Characterisation of cells markers associated with IKZF1plus in BCP-ALL

Maura Rosane Valério Ikoma-Coltutato, Marcia Schramm, Caroline P. Poubel, Mecneide Mendes Lins, Ana Luiza Tardem Maciel, Mariana Emerenciano, Thais Ferraz Aguiar, Bruno A. Lopes, Caroline Barbieri Blunck, Thayana C. Barbosa, Elaine Sobral da Costa, Renan Garcia Gomes, Marcelo Gerardin Poirot Land, Marcela Braga Mansur, Ariadne da Rocha Figueiredo
article en
2 citations

Abstract

The presence of IKZF1 deletions has been associated with an increased relapse rate in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL). There is a particular subset of IKZF1<sup>del</sup> cases called IKZF1<sup>plus</sup> (defined by the co-occurrence of IKZF1<sup>del</sup> and deletions in CDKN2A/B, PAX5, or the PAR1 region, in the absence of ERG deletions), which is also associated with worse prognosis, but some recent studies have not found major differences between the IKZF1<sup>del</sup> and IKZF1<sup>plus</sup> groups. Therefore, the IKZF1<sup>plus</sup> group still needs further comprehension and our study aims to characterise the molecular heterogeneity and identify molecular markers exclusively associated with IKZF1<sup>plus</sup>. Two independent series of cases (TARGET, n = 125 and GenLAb, n = 60) were evaluated by segregating patients into 3 groups: IKZF1<sup>plus</sup>, IKZF1<sup>del</sup>, and IKZF1<sup>wild</sup>. Differential expression analyses showed that the membrane protein-coding genes most associated with the IKZF1<sup>plus</sup> group were: KCNA5, GREB1, EPOR, SDK1, and PTPRB. Notably, KCNA5 and GREB1 differential expression levels were validated in the GenLAb validation series. Regarding copy number alterations, we observed a high frequency of VPREB1 deletions in the IKZF1<sup>plus</sup> group, as well as additional exclusive deletions in the CD200 and BTLA genes. Recent research suggests that the importance of the IKZF1<sup>plus</sup> profile varies depending on the genetic subgroup. In this scenario, we found associations between IKZF1<sup>plus</sup> and certain genes in BCP-ALL, being KCNA5 and GREB1 the most promising biomarkers for predicting IKZF1<sup>plus</sup>. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.

Translational OncologyVol. 50
Universidade Federal do Rio de Janeiro (BR), Blood Cancer UK (GB), Hemorio (BR), Hospital do Câncer III (BR), Pro Criança Cardíaca (BR), Sabin Medicina Diagnostica (Brazil) (BR), Instituto de Medicina Integral Professor Fernando Figueira (BR), Instituto Nacional de Câncer - INCA (BR)
Alexander von Humboldt-Stiftung, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Institut National Du Cancer, Instituto Nacional do Câncer, Ministério da Saúde, National Cancer Institute
Zero hunger
Openalex Percentile: Top 20%
Acute Lymphoblastic Leukemia research
1.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.